For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Avidity Biosciences, Inc.

USPTO Granted Patents = 55

CIPO Patents = 2

EPO Patents = 6

Forward Citations = 387

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

Rob Burke (41 out of 44 patents)

Venkata Ramana Doppalapudi (38 out of 45 patents)

Beatrice Diana Darimont (38 out of 38 patents)

4. Michael Caramian Cochran (35 out of 37 patents)

5. Barbora Malecova (27 out of 27 patents)

6. Andrew John Geall (25 out of 101 patents)

7. David Sai-Ho Chu (21 out of 21 patents)

8. Yunyu Shi (15 out of 15 patents)

9. Gulin Erdogan Marelius (14 out of 19 patents)

10. Michael David Hood (14 out of 14 patents)

11. Rachel Elizabeth Johns (10 out of 10 patents)

12. David Sala Cano (10 out of 10 patents)

13. Hanhua Huang (8 out of 8 patents)

14. Palani Balu (6 out of 14 patents)

15. Arthur A Levin (5 out of 5 patents)

Core Competencies:

Polynucleotide Conjugates

Anti-Transferrin Receptor Antibodies

Muscle Dystrophy

Exon Skipping

Nucleic Acid Compositions

Facioscapulohumeral Dystrophy

Myotonic Dystrophy

Cardiomyopathy

Nucleic Acid-Polypeptide Compositions

PRKAG2-Targeting Antibodies

DMD Exon 44 Skipping

Compositions and Methods

55 patents: Sort by Forward Citations

1. 12760113 - ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF (2026-10-13),

2. 12708669 - POLYNUCLEOTIDE CONJUGATES COMPRISING PLN-TARGETING POLYNUCLEOTIDES AND ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND METHOD OF USE THEREOF TO TREAT PLN-ASSOCIATED CARDIOMYOPATHIES (2026-08-18),

3. 12648999 - COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY (2026-06-09),

4. 12648998 - ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING (2026-06-09),

5. 12529056 - COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (2026-01-20),

6. 12497615 - NUCLEIC ACID COMPOSITIONS AND METHODS OF MULTI-EXON SKIPPING (2025-12-16),

7. 12491257 - COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES (2025-12-09),

8. 12486328 - COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (2025-12-02),

9. 12427202 - Compositions and methods of treating muscle dystrophy (2025-09-30),

10. 12409230 - Compositions comprising PLN-targeting anti-transferrin receptor antibody-polynucleotides and methods of use thereof to treat cardiomyopathy (2025-09-09),

11. 12365704 - Nucleic acid-polypeptide compositions and uses thereof (2025-07-22),

12. 12364769 - Nucleic acid-polypeptide compositions and uses thereof (2025-07-22),

13. 12359202 - Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping (2025-07-15),

14. 12351637 - Nucleic acid-polypeptide compositions and uses thereof (2025-07-08),

15. 12263224 - Compositions and methods of treating muscle atrophy and myotonic dystrophy (2025-04-01),

Company Overview

Avidity Biosciences, Inc. is a biotechnology company based in San Diego, CA, specializing in nucleic acid therapeutics. The company focuses on developing innovative treatments using polynucleotide conjugates and anti-transferrin receptor antibodies. Avidity's research addresses various muscle disorders, including muscle dystrophies, facioscapulohumeral dystrophy, myotonic dystrophy, and cardiomyopathy, aiming to advance therapeutic options through its proprietary technology platform.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

55 Patents

#112 in San Diego, CA

#1,517 in California

#6,460 in US

#12,932 in the World

San Diego, CA, United States of America

Avidity Biosciences, Inc.

Forward Citations = 387

26 inventors:

Rob Burke (41 out of 44 patents)

Venkata Ramana Doppalapudi (38 out of 45 patents)

Beatrice Diana Darimont (38 out of 38 patents)

4. Michael Caramian Cochran (35 out of 37 patents)

5. Barbora Malecova (27 out of 27 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Avidity Biosciences, Inc.. Retrieved from https://idiyas.com/company/avidity-biosciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…